Membrane-bound transporter proteins play an important role in the efflux of drugs from cells and can significantly influence the pharmacokinetics of drug molecules. This study describes the production of large amounts of high-activity transporter membrane vesicles from human embryonic kidney 293-Epstein-Barr virus nuclear antigen cells transiently transfected using a Gateway-adapted pCEP4 plasmid. Transfections were scaled up to 10-liter cell cultures, and vesicle preparations were optimized using ultracentrifugation with a sucrose cushion, which enabled us to produce hundreds of milligrams of membrane vesicles expressing human efflux transporter proteins Pglycoprotein (P-gp)/multidrug resistance 1 (ABCB1), multidrug resistance protein 2 (MRP2) (ABCC2), and breast cancer resistance protein (BCRP) (ABCG2). Assays were developed and optimized for analyzing the ATP-dependent functionality of the transporters using probe substrates and specific inhibitors. Excellent signal/noise ratios of ATP-stimulated uptake for P-gp, MRP2, and BCRP vesicles were obtained, indicating high expression of functioning transporters. The uptake kinetics of the transporters was investigated by determining K m and V max using the model substrates N-methylquinidine (P-gp), estradiol-17␤-glucuronide (MRP2), and estrone-3-sulfate (BCRP). The ATP-dependent transport was inhibited by the model inhibitors verapamil (P-gp), benzbromarone (MRP2), and sulfasalazine (BCRP). The vesicles are thus well suited to screen for possible substrates and inhibitors in high throughput systems or are used for detailed mechanistic investigations of transporter kinetics of specific substances.
Drug transporters present in the plasma membrane are integral membrane proteins that move drugs into or out of the cell. Transporters expressed in organs such as the intestine, liver, and kidney may significantly affect uptake, distribution, and elimination of drugs and are thus important determinants for the pharmacokinetics of a drug molecule. In the liver, efflux transporters expressed in the bile canalicular membrane may significantly extrude drugs into the bile that may affect drug bioavailability and may also be important for drug-drug interactions. The efflux transporters of the ATP-binding cassette (ABC) proteins P-gp/ MDR1 (ABCB1), MRP2 (ABCC2) and BCRP (ABCG2) are reputed to be important for excretion of drugs into the bile. Studies in vitro on the function of efflux transporters are mainly performed using cell systems or vesicle preparations from cell lines or liver tissue. In whole-cell systems the drug efflux can be measured directly only after the cells are loaded with the study compound. Because the cell must first take up the drug before extrusion can be measured, a cell-based assay has obvious constraints, excluding studies on poorly permeable drugs. Furthermore, any detailed studies on the kinetics of drug transport are difficult to conduct because the cellular concentrations are not easily determined. Inside-out membrane vesicles prepared from cells overexpressing a specific transporter are increasingly being used to study the function of efflux transporters. In contrast to the cellular systems the drug interacts directly with the efflux transporter in the vesicular model without the need to first permeate a cell membrane. The kinetics of drug transporter interactions can thus be determined with higher accuracy in a vesicle system than in a cellular system.
Membrane vesicles can be prepared from various sources such as tissue, primary cells, or cell lines transfected with specific transport proteins. The most commonly used cell line for expressing transporter protein and preparing vesicles is insect Sf9 cells (Glavinas et al., 2008) . However, the membrane composition in the insect Sf9 cell plasma membrane is different from than that for mammalian plasma membranes and has been shown to significantly affect transporter functionality (Pál et al., 2007) . In addition, Sf9 insect cell membranes express endogenous efflux transporters, which could confound the results.
The purpose of the present study was to develop a system to produce large quantities of high-activity efflux transporters in mammalian membrane vesicles. Human embryonic kidney 293 (HEK293) cells constitutively expressing the Epstein-Barr virus nuclear antigen (HEK293-EBNA) were used to overexpress the human drug efflux transporters P-gp, MRP2, and BCRP. The HEK293-EBNA cell line was chosen because it exhibits a low background of both uptake and efflux transporters (Ahlin et al., 2008 (Ahlin et al., , 2009 ) and has been used widely for expression of various recombinant proteins (Wurm, 2004) . Moreover, this cell line is amenable to large-scale polyethylenimine (PEI)-mediated transient transfection for large-scale expression of recombinant protein (Tuvesson et al., 2008) . By using this method, high-activity membrane vesicles containing P-gp, MRP2, or BCRP were produced in large quantities from transiently transfected HEK293-EBNA cells.
Materials and Methods
Materials. ATP disodium salt, adenosine 5Ј-(␤,␥-imido)triphosphate tetralithium salt hydrate (AMP-PNP), benzbromarone, estradiol-17␤-glucuronide (E 2 17␤G), estrone-3-sulfate (E 3 S), dimethyl sulfoxide, glutathione, potassium chloride, magnesium chloride, MOPS, sucrose, sulfasalazine, Tris base, and verapamil HCl were purchased from Sigma-Aldrich (Stockholm, Sweden); sodium chloride was from Merck Chemicals Ltd. (Beeston, UK); and [14, 15, 19, Expression of BCRP and MRP2 from Adherent Stable Cell Lines. The pT-REx-BCRP vector for cell transfection was generated by recombination of the entry vector from in-house collection and the pT-Rex-DEST30 Gateway vector (Invitrogen, Stockholm, Sweden). HEK293 cells (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY) were grown in DHI medium (custom version made by SAFC Biosciences, Andover, UK) supplemented with 2 mM glutamine, 10% v/v fetal bovine serum, 500 g/ml G418 (all from Invitrogen), and 1.8 mM CaCl 2 . The Madin-Darby canine kidney II (MDCKII) cell line stably transfected with the MRP2 gene (Cui et al., 1999) was obtained from Prof. D. Keppler (DKFZ, Heidelberg, Germany) . The cells were grown adherently in Dulbecco's modified Eagle's medium/F12 high glucose (4.5 g/l) (SAFC Biosciences) supplemented with 5 mM L-glutamine, 10% (v/v) fetal bovine serum, and 900 g/ml G418.
Adherent cells were grown in static T225 flasks (Corning B.V. Life Sciences, Amsterdam, The Netherlands) at 37°C in 5% CO 2 atmosphere and were routinely passaged twice a week. The production cells were grown in two 6360-cm 2 10-layer Polystyrene CellSTACK chambers (Corning B.V. Life Sciences) for each cell line. Both cell lines (HEK293-BCRP and MDCKII-MRP2) were inoculated to a cell density of 2 ϫ 10 4 cells/cm 2 . The HEK293-BCRP cells were grown for 3 days to 90% confluence and the MDCKII-MRP2 cells were grown for 4 days to 100% confluence. The cells were rinsed once with PBS and harvested using 200 ml of Accutase (PAA Laboratories Ltd., Yeovil, UK). The cell pellets were stored at Ϫ80°C until vesicle preparation.
Expression of MRP2, P-gp, and BCRP from Transient Suspension Cell Cultures. Plasmid construction and preparation. cDNA for MRP2 was obtained from OriGene Technologies (Rockville, MD). The BCRP Entry vector, P-gp cDNA, and the pCEP4GW-EGFP plasmid, used in control transfections, were obtained from in-house collection of vector constructs. Gateway-adapted pCEP4 (pCEP4GW) and pEAK10 (pEAK10GW) destination vectors were obtained from an in-house vector collection (Davies et al., 2005) . MRP2 and P-gp were amplified, and att sites were added by PCR (Table 1) . att-adapted PCR products were purified by electrophoresis on a 1% agarose gel (Bio-Rad Laboratories, Sundbyberg, Sweden), and products of the correct size were excised and extracted using a StrataPrep gel extraction kit (Stratagene, La Jolla, CA). att-adapted MRP2, BCRP, and P-gp PCR products were subcloned into the pCEP4GW and pEAK10GW destination vectors using Gateway technology (Invitrogen) (Fig. 1 ). For construct verification Entry vectors containing the att-adapted MRP2 and P-gp genes were sequenced using gene-specific primers and the CEQ DTCS Quick Start Kit (Beckman Coulter, Bromma, Sweden). Sequencing was performed using a CEQ8000 Genetic Analysis System (Beckman Coulter). DNA sequence analysis and alignments were performed using Lasergene SeqMan II software (version 5.07; DNASTAR, Madison, WI). In silico Gateway cloning and construction of restriction maps were performed using Vector NTI Advance 9 (Invitrogen). Chemically competent Escherichia coli XL1 blue strain organisms (recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [FЈproAB lacI q Z⌬M15 Tn10 (Tet r )]; Stratagene) were transformed with plasmids (Novagen's TB009 user protocol; http://www.emdbiosciences.com). Pure cultures were generated, and glycerol stocks were maintained at Ϫ80°C. Production scale cultures were performed in batch mode in BIOSTAT C vessels (5-liter working volume) (Sartorius BBI, Melsungen, Germany). Fermenter cultures were run at 37°C with dissolved oxygen concentrations no less than 30%. Culture medium was TB (24 g/l Trypton, 12 g/l yeast extract, 17 mM KH 2 PO 4 , and 72 mM K 2 HPO 4 ), and pH was monitored but not controlled. Cultures were harvested in stationary phase, determined by constant OD 600 or declining respiration rate. Plasmid purification was performed using the NucleoBond AX 10000 kit (Macherey-Nagel, Düren, Germany). The manufacturer's instructions were modified as follows to accommodate the low plasmid content in the cell pellet: a larger amount of cell pellet (30 g) was used for plasmid preparation with the total volume of lysate being 1 liter. Centrifugation (8000g for 10 min) was used before filtration for separation of flocs, and subsequent steps were carried out as described in the manual (Macherey-Nagel).
Suspension growth adaptation and cell growth. The adherent cell line HEK293-EBNA (Invitrogen) stably expressing the Epstein-Barr virus nuclear antigen-1 gene was adapted to suspension growth (Davies et al., 2005) in DHI medium supplemented with 4 mM glutamine, 2% (v/v) ultra-low IgG fetal bovine serum, 250 g/ml G418 and 0.1% (w/v) Pluronic F68 (Sigma-Aldrich) for a maximum of 20 passages. For expansion of the seeding culture the cells were grown in plastic shake flasks at 37°C in 5% CO 2 atmosphere at 115 rpm in an orbital shaking incubator (Infors AG, Bottmingen, Switzerland). The cells were routinely passaged when they reached a density of 2 ϫ 10 6 cells/ml. Cell density and viability were measured using a Cedex automatic cell counter (Innovatis AG, Bielefeld, Germany).
Screening of expression conditions. Screening for optimal expression conditions was carried out using 125-ml shake flasks (Corning B.V. Life Sciences) with 40 ml of medium as described previously (Davies et al., 2005) . Conditions investigated were vector type (pCEP4GW or pEAK10GW), concentration of DNA-PEI complex (Table 2) , and time of harvest (2, 3, or 4 days after transfection).
Expression was evaluated by Western blotting of the whole-cell lysates. Cell pellets from 2 ml of culture broth was dissolved in TE buffer (10 mM Tris-HCl and 1 mM EDTA) with 1% (v/v) Triton X-100 and Complete Protease Inhibitor (Roche Diagnostics, Bromma, Sweden). Lysate was mixed with NuPAGE SDS loading buffer (Invitrogen) with 200 mM dithiothreitol without heating. A 7% Tris-acetate gel was loaded with 5 l of sample per well and run at 150 V for 80 min. Western transfer was performed with a NC membrane kit and iBlot equipment (both from Invitrogen). Blocking was performed by incubation for 1 to 2 h with 5% (w/v) nonfat milk. Primary antibodies, mouse anti-MRP2 (Sigma-Aldrich), mouse anti-P-gp (SigmaAldrich), and mouse anti-BCRP (Sigma-Aldrich) were diluted 1:1000 in 5% (w/v) nonfat milk, and blots were incubated for at least 2 h. Secondary antibody anti-mouse horseradish peroxidase conjugate (Cayman Chemical Company, Ann Arbor, MI) was diluted 1:4000 in 5% (w/v) nonfat milk, and blots were incubated for at least 2 h. Chemoluminescence was induced by the SuperSignal West Femto Maximum Sensitivity Substrate (Pierce Chemical, Rockford, IL) and detected using VersaDoc (Bio-Rad Laboratories).
Transfection procedure and production in Wave bioreactors. Large-scale cultures were carried out in 20L Wave bioreactors (Wave Biotech AG, Tagelswangen, Switzerland) with 10 liters of culture volume. Cells were split to a density of 1 ϫ 10 6 cells/ml 1 day before transfection. Cell culture for the production of MRP2 and BCRP was performed as follows. Cells for inoculum (4.5 ϫ 10 9 cells) were centrifuged (300g, 15 min), resuspended in 0.5 liter of fresh DHI medium and transferred to the Wave bioreactor with 4 liters of DHI medium, resulting in a cell density of 1 ϫ 10 6 cells/ml. Cells were allowed to adapt for 2 h before transfection. Transfection mixture (0.5 liter total) was prepared with 2 mg of plasmid DNA and 5 mg of PEI (Tuvesson et al., 2008) and transferred to the culture. Four hours after transfection 5 liters of supplemented DHI medium was added to the culture. Cells were harvested by centrifugation (1500g for 15 min) after 96 h (MRP2) or 72 h (BCRP).
Cell culture for production of P-gp was performed using a simplified protocol. Inoculum was prepared as described above, but the initial volume in the Wave bioreactor was 9 liters with an initial cell density of 0.5 ϫ 10 6 cells/ml. After incubation for 2 h, the culture was transfected by addition of 1 liter of transfection cocktail containing 8 mg of DNA and 20 mg of PEI. Cell pellets were harvested by centrifugation after 72 h and were stored at Ϫ80°C until used in the vesicle preparation.
Immunofluorescence microscopy. For immunostaining of HEK293-EBNA cells transiently transfected with transporter and mock HEK293-EBNA cells transfected with vector alone, cells were attached to Adcell 12-well slides (Thermo Fisher Scientific, Histolab, Sweden). Cells were fixed with 4% formaldehyde in PBS for 15 min at room temperature, washed two times with ice-cold PBS, permeabilized with 0.5% saponin in PBS, washed with PBS (three times) for 5 min, and then blocked (30 min at room temperature) with PBS containing 5% fetal calf serum. Cells were incubated with primary . After incubation, cells were washed three times with PBS for 5 min at room temperature and then once with distilled water. ProLong Gold antifade reagent with 4,6-diamidino-2-phenylindole was added for nuclei staining (Invitrogen). As negative controls for the specific reactivity of the antibodies slides were prepared with secondary antibody added in the absence of primary antibody. Cells were imaged using an Olympus AX70 fluorescence microscope with a 40ϫ or 63ϫ water objective lens. Photographs were taken using a Sony 3CCD video camera. Membrane Vesicle Preparation. Vesicle preparation was performed based on the method described by Keppler et al. (1998) , modified for larger-scale production as described below. Harvested cells were resuspended in lysis buffer (0.5 mM sodium phosphate, 0.1 mM EDTA, pH 7.0, and Complete Protease Inhibitor). Lysis was performed using an Ultra-Turrax T25 homogenizer (IKA Works, Wilmington, NC). The resulting lysate was centrifuged for 10 min at 12,000g. The pellet was resuspended in lysis buffer and homogenized again. Postnuclear supernatant was pooled and centrifuged at 83,000g for 90 min or for 38,000g for 3 h (depending on volume). Pellets were resuspended in incubation buffer (0.25 M sucrose, 10 mM Tris-HCl, pH 7.4, and EDTAfree Complete Protease Inhibitor), resulting in a crude membrane preparation. This solution was layered on top of a sucrose cushion in a 1:1.8 ratio [38% (w/v) sucrose, and 5 mM HEPES-KOH] and centrifuged for 17 h at 28,000 rpm (SW28 rotor, Optima L-100K centrifuge; Beckman Coulter). The turbid interface layer was collected, diluted to 180 ml, and centrifuged for 2.5 h at 82,000g. Pellets were resuspended in incubation buffer and passed through a 27-gauge needle 10 times. The protein concentration was determined using the BCA Protein Assay Kit (Pierce Chemical). All work was performed on ice or at 4°C whenever possible. Cell quantities and solution volumes are given in Table 3 . During the course of preparation of this article the large-scale production method for the vesicles has been repeated with good reproducibility with respect to yields and functional activity.
Transport Studies with Membrane Vesicles. The vesicular transport activity was measured using a rapid filtration technique with a 12-vial system (Millipore rapid filtration apparatus and 1225 sampling manifold) or on 96-well plates (MultiScreen HTS-FB plate; Millipore Corporation, Billerica, MA). After a preincubation period of 5 to 10 min, membrane vesicles (50 g of protein/75-l final reaction volume) were incubated at 37°C (for MRP2 and P-gp) or 32°C (for BCRP) in the presence or absence of 4 mM ATP in assay buffer containing radiolabeled probe substrate (3 Ci/ml) for the indicated times. The uptake reaction was stopped by adding 1 ml of cold washing buffer to the membrane suspension and was then rapidly filtered through a GF/F glass fiber filter (diameter 25 mm, pore size 0.7 M; Whatman, Clifton, NJ) or filter plate. Filters were washed with 2 ϫ 5 ml of ice-cold washing buffer. Filters were transferred to large glass scintillation vials (20 ml) and left to dry at room temperature for at least 2 h before scintillation liquid (10 ml) was added, and the radioactivity retained on the filter was measured using a WinSpectral 1414 liquid scintillation counter (PerkinElmer Life and Analytical Sciences-Wallac Oy, Turku, Finland). For experiments using a 96-well system, the uptake reaction was stopped by adding cold washing buffer, immediately transferring the vesicles to the filter plate, and washing the filter with washing buffer. The filter plate was dried, and radioactivity was measured with a scintillation counter (TopCount NXT; PerkinElmer Life and Analytical Sciences). ATPdependent transport (picomoles of minute per milligram of protein) was calculated by subtracting the values obtained in the absence of ATP from those in the presence of ATP. Assays were performed, at minimum, in triplicate. In control experiments, ATP was replaced by an equal concentration of the nonhydrolyzable ATP analog AMP-PNP.
For vesicular transport experiments with MRP2-expressing vesicles, the assays were performed in assay buffer consisting of 47 mM MOPS-Tris, 65 mM KCl, and 7.0 mM MgCl 2 (pH 7.0), which was supplemented with 2 mM glutathione. The washing buffer consisted of 40 mM MOPS-Tris and 70 mM KCl (pH 7.0). Uptake in MRP2 vesicles of [ 3 H]E 2 17␤G (50 M) was measured at 37°C for 8 min. Benzbromarone was used as the positive control inhibitor of MRP2-mediated transport in the membrane vesicles.
For vesicular transport experiments with BCRP-and P-gp-expressing vesicles, the assays were performed in assay buffer consisting of 10 mM Tris-HCl, 250 mM sucrose, and 10 mM MgCl 2 (pH 7.0), respectively. The washing buffer consisted of 10 mM Tris-HCl, 250 mM sucrose, and 100 mM NaCl (pH 7.0). Uptake in P-gp vesicles of [ 3 H]NMQ (1 M) was measured at 37°C for 2 min. Uptake in BCRP vesicles of [ 3 H]E 3 S (1 M) was measured at 32°C for 1 min. Verapamil and sulfasalazine were used as positive control inhibitors of the transport in the P-gp and BCRP membrane vesicles, respectively. The effect of medium osmolarity was investigated by measuring the ATPdependent uptake in the presence of increasing sucrose concentrations (increasing medium osmolarity).
Data Analysis. Curve-fitting was performed using XLfit 4.2.2 software. K m and V max values from vesicle transport experiment were calculated using the Michaelis-Menten equation:
where V is the uptake velocity (picomoles of substrate per minute per milligram of protein), V max is the maximum uptake velocity, S is the substrate concentration (micromolar), and K m is the Michaelis-Menten constant. The transport of estradiol-17␤-glucuronide in MRP2 vesicles did not follow simple Michaelis-Menten kinetics and in this case the Hill equation for sigmoidal transport kinetics was used:
where K 0.5 is the half-maximal rate and n is the Hill slope factor indicating the degree of cooperativity and suggesting the presence of more than one binding site.
IC 50 values for different transporter control inhibitors were calculated using the following equation:
This equation fits inhibition data to a two-parameter equation, where the lower data limit is 0 and the upper limit is 100. IC 50 is the concentration of the inhibitor leading to half-maximal inhibition, x is the inhibitor concentration, and n is the slope factor.
Results

att Adaption of Transporters and Entry Vector Sequence Analy-
sis. An adapted two-step PCR process (Kagawa et al., 2004) was required for the att adaption of the MRP2 and P-gp. The att-adapted constructs were sequenced and found to be in agreement with published amino acid sequences (NM_004827, NM_000927, and NM_000392 for BCRP, P-gp, and MRP2, respectively) with the exception of MRP2 for which the amino acid change V417I was observed. This is a conservative amino acid change and is not expected to have any effect on the transporter activity. Expression Tests in Small-Scale Suspension Cultures. The two expression vectors (pCEP4GW and pEAK10GW), the DNA/PEI concentration, and the optimal time of harvest were initially tested in small-scale suspension cultures. Evaluation by Western blot showed that for all transporters pCEP4GW-based constructs gave higher expression levels compared with pEAK10GW-based constructs. Expression in pCEP4GW cultures resulted in a high level of expression after 48 h and remained constant until 96 h after transfection, thus providing a wide window for harvest. A representative result for BCRP expression is shown in Fig. 2 .
Cell growth and viability were negatively affected by transfection in all cultures. Whereas untransfected controls exhibited 99% viability, the cells in transfected cultures declined to approximately 50% viability in the worst case (Fig. 3) . To discriminate between the effect of recombinant protein expression and PEI alone we included a control with PEI only (2 g/ml). The result shows that toxicity of PEI was a major reason for slower cell growth and decline in viability (Fig. 3) . Recombinant protein expression accounted for a smaller additional effect. Western blots revealed that higher DNA/PEI levels improved P-gp expression, but led to decreased levels of MRP2 and BCRP expression.
The conditions selected for large-scale cultures were pCEP4GW-based constructs: lower concentrations of DNA (0.4 g/ml) and PEI (1 g/ml) for BCRP and MRP2, but higher concentrations of DNA (0.8 g/ml) and PEI (2 g/ml) for P-gp. Because the expression levels did not significantly change between 48 and 96 h, the harvest could be performed between these times.
Expression of P-gp, MRP2, and BCRP in transiently transfected HEK293-EBNA cells was further analyzed by immunofluorescence microscopy. Transfected HEK293-EBNA cells immunostained specifically for P-gp (clone F4), MRP2 (M2 III-6), or BCRP (BXP-21) showed intense fluorescence signal, which appeared to be predominantly localized to the plasma membrane (Fig. 4) . This observation was further supported using confocal laser scanning microscopy (data not shown). Under the same conditions, the endogenous expression of P-gp, MRP2, or BCRP were not detectable in the mock HEK293-EBNA cells transfected with the vector alone (Fig. 4) .
BCRP and MRP2 were expressed in adherent stable cell lines using 10-layer cell stacks. The expression levels in these cells were compared with the best conditions for transiently transfected cells. Western blotting revealed a higher expression of both MRP2 and BCRP in transiently transfected cells compared with stable transfections (data not shown). The higher expression levels in transiently transfected cells and the potential for scale-up of suspension cell cultures encouraged us to continue with the transient transfection system. Large-Scale Transient Transfection Suspension Cultures. The cultures with MRP2 and BCRP were performed according to the largescale protocol published earlier (Tuvesson et al., 2008) . The transfection was carried out at a cell density of 1.0 ϫ 10 6 cells/ml in half of the final volume for several hours, after which the remaining medium was added. The rationale behind this protocol is that transfection at a higher cell density is more efficient and at the same time reduces the required plasmid quantity by half, which is important for large-scale cultures. Although this method has achieved satisfactory results in the past we discovered that expression levels of MRP2 and BCRP in large-scale cultures were lower compared with small-scale expression tests (Fig. 5) . This result showed that cell density at transfection is a very important parameter, and the subsequent cultures with P-gp were scaled-up, strictly following the best conditions achieved in a small scale, i.e., at a cell density of 0.5 ϫ 10 6 cells/ml. As a result, the expression level of P-gp in the large scale exceeded that of small-scale cultures (Fig. 5) .
Vesicle Preparation. Expressed transporters localized in the plasma membrane were recovered using established cell fractionation techniques (Huber et al., 2003) . The postnuclear supernatant, which was obtained by homogenization and short centrifugation to remove intact cells and nuclei, contained membranes and other organelles. Membrane-bound transporter proteins were recovered by high-speed centrifugation as a crude preparation. Ultracentrifugation on a sucrose cushion was used to fractionate preparations to enrich lower-density lipid-rich fractions, including endoplasmic reticulum membranes. The interface fraction on top of the 38% (w/v) sucrose cushion was added to the final buffer. The recovery of transporter protein in the preparation method was evaluated by Western blotting of the fractions and showed essentially the same result for all three transporters. Densitometric analysis of Western blots showed that the recovery of the transporter proteins in the final product ranged from 48 to 70% of the amount detected in the whole-cell lysate (data not shown).
Functional Transporter Activity. The vesicles prepared from HEK293-EBNA cells transiently transfected with P-gp, MRP2, or BCRP showed a prominent ATP-dependent substrate uptake, indicating high functional transporter activity (Fig. 6) . In contrast, no significant ATP-dependent uptake of the probe substrates was observed in vesicles from mock-transfected cells (Fig. 6) . In a series of control experiments, uptake in the transporter vesicles and mock vesicles was measured when ATP was replaced by an equal concentration of (Fig. 7) . For both transporter vesicles and mock vesicles AMP-PNP did not stimulate uptake of the probe substrates, and there was no difference in uptake rate values in the presence of AMP-PNP compared with uptake rates obtained in the absence of ATP (Fig. 7) . Thus, rates of ATP-dependent uptake of the probe substrates in the P-gp, MRP2, and BCRP vesicles, calculated by subtracting values in the absence of ATP or presence of AMP-PNP as control from those in the presence of ATP, were equal. These results indicated that the measured ATP-dependent transport in the vesicles was an active transporter-mediated process requiring hydrolysis of ATP and rule out binding of substrates to membrane and transporters themselves in the presence of ATP. To confirm that the observed ATP-dependent uptake of probe substrates reflects transport into a vesicular space, the effect of extravesicular medium osmolarity on the uptake was investigated (Fig. 8) . The ATP-dependent transport of probe substrates in P-gp, MRP2, or BCRP vesicles decreased with increasing sucrose concentration (osmolarity) (Fig. 8) . These results indicate that the ATP-dependent transport of probe substrates occurred into an osmotically sensitive space and not with binding to the vesicle surface. No ATP-dependent uptake of the probe substrates was observed in vesicles from mocktransfected cells irrespective of medium osmolarity.
All activity measurements were optimized to obtain linear conditions for time and amount of vesicles in the incubations. With use of the optimized experimental conditions excellent signal/background ratios (ratio of transport ϩATP/ϪATP) and level of ATP-dependent uptake were measured for the probe substrates (Table 4 ). The ATPdependent uptake of probe substrates in MRP2-and BCRP-expressing membrane vesicles prepared from stably transfected MDCKII and HEK293 cells was found to be 50-and 6-fold lower, respectively, than that obtained in the transiently transfected HEK293-EBNA cells (Fig. 9) .
The concentration dependence of the ATP-dependent transport of model substrates in the P-gp, MRP2, and BCRP transporter vesicles FIG. 3 . Viable cell count (A) and viability (B) of HEK293-EBNA cells during expression tests of transporters MRP2, BCRP, and P-gp using pCEP4GW or pEAK10GW vectors and the low or high concentration of DNA-PEI complex. For pCEP4GW, the low and high concentrations of DNA/PEI were 0.4/1.0 and 0.8/2.0 g/ml, respectively. For pEAK10GW, the low and high concentrations of DNA/PEI were 0.5/1.0 and 1.0/2.0 g/ml, respectively. The EGFP construct was in the pCEP4GW vector and was transfected at the high DNA/PEI concentration (0.8 g/ml DNA ϩ 2 g/ml PEI). was characterized (Fig. 10) . NMQ was transported in the P-gp vesicles with a K m value of 2.9 M and a V max value of 1449 pmol/mg/ min. The transport kinetics for E 3 S in the BCRP vesicles showed a K m value of 11 M and a V max value of 1643 pmol/mg/min. E 2 17␤G showed sigmoidal concentration-dependent uptake kinetics with a Hill slope factor of 2.1, which suggests the involvement of more than one binding site on the transporter protein. Well characterized transporter inhibitors abolished the ATP-dependent uptake of the probe substrates. Transport of NMQ (1 M) was inhibited by the P-gp inhibitor verapamil with an IC 50 value of 2.7 M, the MRP2 inhibitor benzbromarone inhibited E 2 17␤G (50 M) transport with an IC 50 value of 106 M, and the BCRP inhibitor sulfasalazine inhibited E 3 S (1 M) with an IC 50 value of 0.6 M (Fig. 11) .
Discussion
The main objective of this study was to develop a system to produce large quantities of high-activity efflux transporters in mammalian membrane vesicles. The results from the present study show that the HEK293-EBNA cell line is suitable for the overexpression by transient transfection of and for the production of large quantities of human P-gp, MRP2, and BCRP membrane vesicles. The transporter vesicles showed high activity toward model substrates and exhibited saturable uptake kinetics, and uptake was sensitive to known inhibitors of each respective transporter. The transport of substrates in the vesicles was shown to be an active transporter-mediated process requiring hydrolysis of ATP. Any binding of substrates to membrane and transporters themselves in the presence of ATP was ruled out. The drug transporters were also found to be expressed at the cell surface as shown by immunofluorescence microscopy, indicating correct expression and position of the transporters.
Two widely used methods for production of recombinant proteins in mammalian cells are the modified baculovirus (BacMam virus) process and transient transfection using nonviral plasmid vectors (Wurm and Bernard, 1999) . Both BacMam and plasmid-based transient transfection share the advantage that a variety of proteins can be expressed using different stocks of virus or plasmids, whereas only a single mammalian cell line has to be maintained. Plasmid DNA can be bulk-produced and stored long-term (several years) ready for transfection, whereas storage of baculovirus is limited to a few months at ϩ4°C. Transient transfection mediated by FuGENE6 reagent has been successfully used for small-scale BCRP production (Mohrmann et al., 2005) . Recent advances in large-scale PEI-mediated transient transfection (Tuvesson et al., 2008) enabled us to apply this technique for the large-scale expression of human ABC transporters.
The HEK293 cells express low endogenous levels of transporters, which make them suitable for overexpression of target transporters (Ahlin et al., 2008 (Ahlin et al., , 2009 ). These cells could therefore be used as a common cell system for the overexpression of not only uptake transporters but also efflux transporters. Membrane proteins expressed in Sf9 cells are underglycosylated, and it has been suggested that the (Telbisz et al., 2007) . Plasma membranes of insect cells such as Sf9 contain low levels of endogenous cholesterol in comparison with mammalian cells. Cholesterol is suggested to be an important component in the plasma membrane for transporter function. Telbisz et al. (2007) found that cholesterol loading of Sf9 cells enhanced the BCRP transporter activity, whereas cholesterol depletion of intact mammalian cells significantly reduced BCRP-dependent transport activity. In our study, the functional activity of the transporter vesicles produced from transiently transfected HEK293-EBNA cells was excellent as shown by a signal/background ratio (ratio of transport in the absence and presence of ATP) in the range of 5 to 40 and a high level of ATP-dependent transport. The functional activity was found to correlate well with the expression level detected by Western blotting, indicating that it can be used as a quality control measure during vesicle production. Samples of vesicles were removed throughout the preparation process and the uptake activity in the vesicle fractions was analyzed. The results of this analysis demonstrated that the sucrose gradient centrifugation step was critical to obtain enrichment of vesicles with high uptake activity (data not shown). The efflux transporter assays presented in this study are all based on transporter transfections with a verified amino acid sequence that corresponds to the wild-type sequence. The functional uptake activity in vesicles prepared from the transiently transfected cells was higher than that of vesicles prepared from stably transfected cells. In our hands, the level of activity in these vesicles as indicated by V max values (picomoles per minute per milligram of protein) for probe substrates used in this study is even higher than that reported for MRP2 (Zelcer et al., 2003; Telbisz et al., 2007; Pedersen et al., 2008; Herédi-Szabó et al., 2009) , BCRP (Pál et al., 2007 , Xia et al., 2007 , and P-gp (Hooiveld et al., 2002) vesicles prepared from Sf9 cells. The transient transfection approach and large-scale production technologies described in this study should be generally applicable for other ABC efflux transporters of interest, e.g., MRP3, MRP4, and bile salt export pump.
In this study, the transport kinetics for E 2 17␤G uptake by MRP2 was sigmoidal with an estimated half-maximal transport rate (K 0.5 ) of 146 M and a Hill number of 2.1. These results are in agreement with previous reports proposing that MRP2 contains two interacting binding sites (Bodo et al., 2003; Zelcer et al., 2003) . Results similar to our data were reported by Zelcer et al. (2003) and Herédi-Szabó et al. (2009) , who had K 0.5 values of 120 and 150 M, respectively, for E 2 17␤G transport in MRP2 membrane vesicles prepared from baculovirus-infected Sf9 cells. The K m value for transport of NMQ in our P-gp vesicles was 2.9 M, which is lower than the K m value of 14.7 M reported for the transport of this substrate into membrane vesicles prepared from P-gp-overexpressing Sf21 insect cells (Hooiveld et al., 2002) . The observed differences in affinity might be related to the effect of membrane cholesterol on the P-gp transporter because the Sf9 insect cell membranes contain less cholesterol than the mammalian HEK293 cell membranes (Eckford and Sharom, 2008) .
The membrane vesicles can be used in vesicular transport assays to assess whether the drug is a substrate and/or inhibitor of the transporter. High specific transporter activity of the vesicles is important to be able to identify transporter substrates. P-gp substrates are often lipophilic and highly membrane-permeable, resulting in high passive uptake into the vesicles, masking the contribution of active P-gp transport. The results of this study support previously reported data indicating that NMQ, a low permeability cationic compound, is a suitable P-gp substrate to use in a vesicle-based P-gp inhibition assay (Hooiveld et al., 2002) .
In addition to investigating whether compounds may be substrates, the membrane vesicles are also suitable for use in inhibition assays. The radiolabeled probe substrates used in our characterization studies showed excellent sensitivity and known efflux inhibitors inhibited the uptake. Investigations of possible inhibition of specific transporters by drug candidates could predict drug transporters interactions. Transporter drug interactions are a relatively new area of investigation and for the efflux transporters attention has been focused mainly on P-gp (Zhang et al., 2008) . The results from the present study indicate that the high-activity human P-gp membrane vesicles could potentially be used as an alternative to the commonly used P-gp inhibition assays in Caco-2 or MDCK-MDR1 cell monolayers with digoxin as the probe substrate.
The vesicle system can be easily applied in a high-throughput format, screening for both substrate and inhibitors of the individual transporter. By using vesicles the investigated drug is in direct contact with the efflux transporter, which implies that the determination of kinetic parameters, K m values for substrates, and K i /IC 50 values for inhibitors are more accurate (closer to true values) than the corresponding values determined in the cell monolayer systems, in which there is a basolateral membrane to traverse to reach the transporter protein of interest.
In conclusion, this study shows that high-activity membrane vesicles containing P-gp, MRP2, or BCRP can be produced in large quantities from transiently transfected HEK293-EBNA cells. This approach for the preparation of membrane vesicles should be generally applicable to the production of vesicles of other human ABC efflux transporters that are expressed in a human cell membrane.
